Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Ian Gould, PhD, Jan Bassali, PharmD, Jyotsna Mehta, Jatin Shah, MD, Dee Dee Mladsi, BA

Blood (2019) 134 (Supplement_1): 5824.

https://doi.org/10.1182/blood-2019-125997

Published: 2019

Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA

Blood (2019) 134 (Supplement_1): 5852.

https://doi.org/10.1182/blood-2019-122709

Published: 2019

Journal Articles

Microcosting and Budget Impact Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi

Matthew Painschab, MD, Racquel E Kohler, PhD, Satish Gopal, MD MPH

Blood (2018) 132 (Supplement 1): 3558.

https://doi.org/10.1182/blood-2018-99-115237

Published: 2018

Journal Articles

Budget Impact of First-Line Bosutinib for Chronic Phase Chronic Myeloid Leukemia on a US Health Plan

Verna L Welch, PhD MPH, CPEHR, CPHIMS, Peter Quon, MPH, Denise Zou, Jennifer Uyei, PhD MPH, Sherry Wu, MPH, Ying Xiao, Carla M. Mamolo, PhD

Blood (2018) 132 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2018-99-110544

Published: 2018

Journal Articles

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Ivar S Jensen, MBA, Elizabeth Wu, Naomi Sacks, Philip Cyr, MPH, Karen Chung

Blood (2017) 130 (Supplement 1): 5615.

https://doi.org/10.1182/blood.V130.Suppl_1.5615.5615

Published: 2017

Journal Articles

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4668.

https://doi.org/10.1182/blood.V130.Suppl_1.4668.4668

Published: 2017

Journal Articles

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Sri Adapa, BSPharm, MBA, Olga Ovcinnikova, MSc, Ian Leighton, PhD, Shamika de Silva, PhD, Matthew Bending, PhD, Larisa Belyanskaya, PhD, Cosentino Lidia, PhD, Anne Myerson, MSc

Blood (2017) 130 (Supplement 1): 4929.

https://doi.org/10.1182/blood.V130.Suppl_1.4929.4929

Published: 2017

Journal Articles

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Ravi Potluri, Hitesh Bhandari, Sandip Ranjan, Clara Chen, PhD MS

Blood (2016) 128 (22): 2363.

https://doi.org/10.1182/blood.V128.22.2363.2363

Published: 2016

Journal Articles

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Andrzej Jakubowiak, MD PhD, Istvan Matyas Majer, PhD, Ivan Houisse, MSc, Agnes Benedict, Marco Campioni, Sumeet Panjabi, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 3582.

https://doi.org/10.1182/blood.V128.22.3582.3582

Published: 2016

Journal Articles

Budget Impact Analysis of Treating Chemotherapy Patients with Patient-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Holly Trautman, Erika Szabo, Francesco Lo-Coco, Elizabeth James, Susan Gabriel, Jifang Zhou, Ashutosh Pathak, Boxiong Tang

Blood (2016) 128 (22): 4786.

https://doi.org/10.1182/blood.V128.22.4786.4786

Published: 2016

Journal Articles

Budget Impact Analysis of Treating Chemotherapy Patients with Health Care Provider-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Holly Trautman, Erika Szabo, Francesco Lo-Coco, Elizabeth James, Susan Gabriel, Jifang Zhou, Ashutosh Pathak, Boxiong Tang

Blood (2016) 128 (22): 2407.

https://doi.org/10.1182/blood.V128.22.2407.2407

Published: 2016

Journal Articles

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

Victoria Divino, Mitch Dekoven, MHSA, Weiying Wang, MPH, Michael Kleinrock, MA, R. Donald Harvey, PharmD, Rolin L Wade, RPh, MS, Satyin Kaura, MSci, MBA

Blood (2014) 124 (21): 736.

https://doi.org/10.1182/blood.V124.21.736.736

Published: 2014

Journal Articles

Funding mechanisms and program management at the National Heart, Lung, and Blood Institute: confronting new challenges and exploring new opportunities

Susan B. Shurin

Blood (2011) 118 (20): 5380–5382.

https://doi.org/10.1182/blood-2011-08-372367

Published: 2011

Journal Articles

A Cost-Utility and Budget Impact Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Severe Thalassemic Patients In Thailand.

Suradej Hongeng, Samart Pakakasama, Nongnuch Sirachainan, MD, Ampaiwan Chuansumrit

Blood (2010) 116 (21): 1536.

https://doi.org/10.1182/blood.V116.21.1536.1536

Published: 2010

Journal Articles

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches.

Edgar Braendle, MD, PhD, Peter Hudson, M.Sc, Ossa Diego, Ph.D, Ratcliffe Mark, Ph.D

Blood (2010) 116 (21): 4489.

https://doi.org/10.1182/blood.V116.21.4489.4489

Published: 2010

Journal Articles

Notes from the Director, National Heart, Lung, and Blood Institute: transitions

Elizabeth G. Nabel

Blood (2009) 113 (13): 2875–2877.

https://doi.org/10.1182/blood-2008-12-194100

Published: 2009

Journal Articles

Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)

Bruce Feinberg, DO, Jeffrey Scott, MD, Susan Weidner, Barry Fortner, PhD

Blood (2008) 112 (11): 2397.

https://doi.org/10.1182/blood.V112.11.2397.2397

Published: 2008

Journal Articles

Response: “Lesser” ALL: should it be studied further as research budgets are diminishing?

James H. Feusner

Blood (2008) 111 (1): 469.

https://doi.org/10.1182/blood-2007-10-116004

Published: 2008

Journal Articles

A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US.

D.S. Pete Fullerton, Holly Trautman, Hui Huang, Jelena Veljkovic, Dixie-Lee Esseltine, Jing Marantz

Blood (2007) 110 (11): 3324.

https://doi.org/10.1182/blood.V110.11.3324.3324

Published: 2007

Journal Articles

Notes from the Director, National Heart, Lung, and Blood Institute: NHLBI core values and shaping the 2007 budget

Elizabeth G. Nabel, Susan B. Shurin

Blood (2007) 110 (4): 1091.

https://doi.org/10.1182/blood-2007-05-089607

Published: 2007

NARROW

A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Microcosting and Budget Impact Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi

Budget Impact of First-Line Bosutinib for Chronic Phase Chronic Myeloid Leukemia on a US Health Plan

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Budget Impact Analysis of Introducing Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A US Payer Perspective

Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)

Budget Impact Analysis of Treating Chemotherapy Patients with Patient-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

Budget Impact Analysis of Treating Chemotherapy Patients with Health Care Provider-Administered Tbo-Filgrastim, Filgrastim-Sndz, and Filgrastim in the United States

The Budget Impact of Orphan Drugs in the U.S.: A 2007-2013 MIDAS Sales Data Analysis

Funding mechanisms and program management at the National Heart, Lung, and Blood Institute: confronting new challenges and exploring new opportunities

A Cost-Utility and Budget Impact Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Severe Thalassemic Patients In Thailand.

Molecular Testing for Response to Treatment for Chronic Myeloid Leukemia (CML) Patients: Information Available to Decision Makers on the Costs and Analytical and Clinical Validity of Alternative Approaches.

Notes from the Director, National Heart, Lung, and Blood Institute: transitions

Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)

Response: “Lesser” ALL: should it be studied further as research budgets are diminishing?

A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US.

Notes from the Director, National Heart, Lung, and Blood Institute: NHLBI core values and shaping the 2007 budget

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only